We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Proteome Sciences Plc | LSE:PRM | London | Ordinary Share | GB0003104196 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.65 | 0.00 | 13:55:29 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 2.30 | 3.00 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 5.03M | -2.44M | -0.0083 | -3.19 | 7.82M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 2.65 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 13/9/2024 | 06:00 | UK RNS | Proteome Sciences PLC Interim Results and Directorate Change |
| 16/5/2024 | 12:10 | UK RNS | Proteome Sciences PLC Result of AGM |
| 16/5/2024 | 11:23 | ALNC |  IN BRIEF: Proteome Sciences promises AGM return to growth in 2024 |
| 16/5/2024 | 06:00 | UK RNS | Proteome Sciences PLC AGM Statement |
| 26/4/2024 | 10:18 | ALNC | Proteome wins GBP500,000 deal to supply mass spectrometry services |
| 26/4/2024 | 06:00 | UK RNS | Proteome Sciences PLC Contract Win |
| 10/4/2024 | 10:26 | ALNC | Proteome Sciences shares drop as revenue plunges and swings to loss |
| 10/4/2024 | 06:00 | UK RNS | Proteome Sciences PLC Final Results |
| 02/1/2024 | 10:52 | ALNC | IN BRIEF: Proteome Sciences says San Diego lab now fully operational |
| 02/1/2024 | 07:00 | UKREG | Proteome Sciences PLC Completion of new facility in San Diego |
Proteome Sciences (PRM) Share Charts1 Year Proteome Sciences Chart |
|
1 Month Proteome Sciences Chart |
Intraday Proteome Sciences Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 14/12/2024 | 10:11 | Proteome Sciences leading Alzheimer's technology. | 93,237 |
| 14/12/2024 | 07:54 | Proteome, what next? (moderated) | 59,869 |
| 13/9/2024 | 08:30 | Does Fgnoms really have to say the same thing all the time thread | 27 |
| 13/5/2020 | 18:36 | Only worth 3p on fundamentals.... | 10 |
| 28/4/2020 | 06:22 | Proteome Sciences plc, A Three Horse Race for the Month of May. | 4,854 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 15/12/2024 08:20 by Proteome Sciences Daily Update Proteome Sciences Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker PRM. The last closing price for Proteome Sciences was 2.65p.Proteome Sciences currently has 295,182,056 shares in issue. The market capitalisation of Proteome Sciences is £7,822,324. Proteome Sciences has a price to earnings ratio (PE ratio) of -3.19. This morning PRM shares opened at - |
Posted at 12/12/2024 11:04 by barry evans Golly Blackwell - 29 Jun 2011 - 13:16:26 - 1190 of 93231 Proteome Sciences leading Alzheimer's technology. - PRMWith respect notready, This was only ever a fruit machine money stock, surely? |
Posted at 11/12/2024 17:36 by canaletto Is there a cure for crooked Chairmen?Prm might as well try and get a Biomarker for that because they sure as hell have as much chance of finding success with Alzheimer's as my sister NNN. ? |
Posted at 05/12/2024 18:05 by canaletto Who would have thunk that Bitcoin would have beaten PRM to being a decent investment? |
Posted at 27/11/2024 07:21 by wrighty41 Very surprised at the lack of notifiable commercial progress by PRM this year, as represented by the share price.Earlier in the year PRM said that 2024 would see a ‘return ro growth’. If this isn’t delivered then it will be a huge disappointment. W41 |
Posted at 31/10/2024 11:21 by wrighty41 The commercial progress PRM have made this year has been very disappointing & has resulted in yet another CEO ‘walking away’.I was hoping for a 6p share price by y/e 2024 but that now seems to have been wildly optimistic! W41 |
Posted at 17/10/2024 12:12 by barry evans wasjobber - 05 Jul 2011 - 10:01:20 - 1612 of 93165 Proteome Sciences leading Alzheimer's technology. - PRMFrom the recent annual report. PRM are now in the last stage of their development, commercialization of their hugely valuable IP portfolio and products. Very interesting times lay ahead me thinks! |
Posted at 13/9/2024 08:28 by stocktastic HelloI looked in on the PRM share price last night for the first time in many months. Funnily, just before the interim today. So, Mariola is off. Not too clear what she achieved? Services 'healthy' Hmmm, £40k revenue in 6 months is less than what my local plumber would get. So the company plods on. Still no real hope of investors getting returns.... Still crooks like pools2 spout made up ramps Nothing changes |
Posted at 22/7/2024 11:27 by sandcrab2 The excellent Fgnoms covered this 13 years ago“fgnoms30 Apr '11 - 10:28 - 14 of 26 0 0 0 Well here we are at the end of April and still no commercial money-making contracts have been signed. CJP at the time of the money raising reiterated break even for 2010, which would have required a few such contracts to have been signed in say late Q3 2010. So seven months on and NO such deals have been signed. I guess the important question is why? Of course we have suffered the same sorry story for the last 4 years on stroke. Yes 4 years ago contracts were imminent and apparently still are but we haven't been told why they haven't been signed. The obvious explanation is that PRM stroke biomarkers together with other panel constituents don't work well enough and therefore a stroke panel cannot be commercialised. Remember all those companies testing the PRM stroke biomarkers - and absolutely nothing has resulted. I think it would now be reasonable to assume that stroke is dead. So what about AD. Yes we are now at the same stage as stroke was 4 years ago. Tests are being carried out - but this time by PRM itself. This indicates to me that none of the big boys have any faith whatsoever in PRM's AD biomarkers - especially since the Dutch revelation that Clusterin isn't a predictive biomarker. So why does PRM continue to lead us on that a commercial deal is just around the corner. I find this bizarre. As PRM is now carrying out its own tests on its own panel nobody is going to sign anything until the results are known - which will probably be in H1 2012. And even then it really isn't feasible that a final saleable AD working panel will only contain PRM biomarkers, is it? So in my view we are years away from a working AD panel. So where does all this optimism come from - cloud cuckoo land imho. So before my next post we will know the 2010 results - a complete disaster no doubt. A loss of nearly £5m compared with target breakeven. 2011 is also looking like another £5m loss as I don't believe any commercial contracts will be signed. 2012 may not be much better either and thats when the cash runs out. So what will the share price be when all this is revealed next month? A very far cry from anything the rampers are saying thats for sure.” |
Posted at 22/7/2024 09:51 by barry evans re 92987For the benefit of those that have the avatar goatherd filtered and will not have been able to view this (It is quite something): wasjobber 22 Jul '24 - 10:18 - 59772 of 59774 0 1 0 I wonder how high Proteome Sciences share price will rise after Randox announce the release of their clinical Stroke test in blood? pools2 22 Jul '24 - 10:31 - 59773 of 59774 0 0 0 wasjobber, PRM's share price should rise significantly after Randoz release their clinical Stroke test. It could also rise before the release date. wasjobber 22 Jul '24 - 10:43 - 59774 of 59774 0 0 0 Thanks pools2 |
Posted at 07/3/2024 18:40 by wrighty41 The current CEO of PRM is proving herself to be uninspiring imo.I’m still hopeful we may see 6p+ on the share price this year but without any update from PRM on the forward looking revenue outlook for 2024 it’s difficult to say. We’ll get the FY results over next couple of months. The forward guidance will be critical for share price progress. W41 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
